Meridian Bioscience Stock

Meridian Bioscience Capital Expenditures

The Capital Expenditures (CapEx) of Meridian Bioscience (VIVO) as of Aug 10, 2026 is -8.62 M USD. In the previous year, Capital Expenditures (CapEx) was -18.31 M USD — a change of -52.95% (higher).

Capital Expenditures

-8.62 MUSD

YoY

-52.95%

Last updated:

Capital Expenditures (CapEx) of Meridian Bioscience is 2026 -8.62 M USD. Capital Expenditures (CapEx) of Meridian Bioscience was 2025 -18.31 M USD. It decreases by -52.95% higher compared to the previous year.
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Capital Expenditures (CapEx) of Meridian Bioscience is -8.62 M USD in 2026.

Capital Expenditures (CapEx) of Meridian Bioscience changed from -18.31 M USD to -8.62 M USD, representing a -52.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Meridian Bioscience

All Key Metrics — Meridian Bioscience